WonderBiotics vs Seed DS-01: Best for GLP-1 Users?

WonderBiotics Probiotics for Gut Health vs Seed DS-01 for Semaglutide Users

If you're on semaglutide or tirzepatide and shopping for gut support: Seed DS-01 has the larger, more recently published placebo-controlled trial behind its full 24-strain formula^{1, 2}, while WonderBiotics Probiotics for Gut Health pairs a smaller, digestive-focused strain lineup with a food-breakdown enzyme blend at a lower price. Neither has been tested specifically in people taking a GLP-1 medication.

How Seed DS-01 and WonderBiotics Probiotics for Gut Health Differ

Seed's DS-01 packs 24 probiotic strains into 53.64 billion AFU (Active Fluorescent Units, a flow-cytometry-based viability count some brands use instead of CFU), but only about 38.7 billion of that total sits in the "digestive health" blend¹. The rest is split across separate dermatological, cardiovascular, and micronutrient-synthesis blends. If digestion is your only goal, some of what you're paying for is earmarked for other jobs.

WonderBiotics Probiotics for Gut Health takes a different approach: all 60 billion CFU across its 12 strains sit in a single digestion-focused formula rather than split across separate blends the way Seed's is, including Bifidobacterium animalis subsp. lactis HN019, Lactobacillus acidophilus NCFM, and Lacticaseibacillus rhamnosus GG⁴. It also adds a five-enzyme blend (amylase, protease, lactase, cellulase, and lipase) plus a fructooligosaccharide (FOS) prebiotic⁴, which Seed's formula doesn't include.

Among the strains each company discloses by name, none share an exact strain code, so head-to-head comparisons aren't possible. A study on one company's coded strain doesn't transfer to a similarly named strain from a different supplier, even within the same species.

Seed's capsule is the more engineered piece of hardware here. ViaCap is a two-part capsule: the outer shell is described as a "non-fiber prebiotic" that dissolves first, and the inner capsule holds the 24 probiotic strains for release further down the GI tract¹. A lab study funded by Seed and co-authored by Seed employees ran the finished formula through a gut-simulation system (SHIME): the share of cells that were still alive fell to about 26% after the simulated stomach phase, then rose back to roughly 45–46% by the middle and end of the simulated small intestine³. Those are viability percentages within each sampled batch, not the fraction of the starting dose that survived; the study didn't report survival as a percent of the initial cell count. It's a lab simulation rather than a measurement inside a living gut, colon-stage survival wasn't tested, and Seed funded and co-authored the study.

WonderBiotics doesn't publish an equivalent capsule-engineering study for its Gut Health formula. Where it keeps things simpler is capsule count and cost: one capsule instead of two, and a lower monthly price at every subscription tier⁴.

What the Clinical Evidence Shows for Bloating, Gas, and Regularity

Seed's evidence. In January 2026, Nutrients published a randomized, double-blind, placebo-controlled trial of the complete DS-01 formula in 350 "otherwise healthy" adults with self-reported bloating or indigestion lasting three months or longer (not a diagnosed condition like IBS)². Of those 350, 219 had evaluable data at week 6; the analysis included participants with at least one week of adherent post-baseline data, and missing data for the final two timepoints was carried forward from the last observation². Attrition was substantial enough to weigh when reading the results. The pre-specified primary endpoint, GI-related quality of life at week 6, favored DS-01 over placebo (median score 0.80 vs. 1.20, P<0.05)². Pre-specified secondary endpoints also favored DS-01: less bloating/gas on the PROMIS-GI 13a scale (P<0.01) and less abdominal discomfort on PROMIS-GI 5a (P<0.01). Additional lower-GI outcomes, tracked separately from those secondary endpoints, also favored DS-01: higher rates of "no or slight constipation" and "improved regularity" (both P<0.05)². The trial was funded by Seed Health; two of the listed authors are Seed employees and shareholders, and two more disclosed serving as paid advisors to Seed².

WonderBiotics' evidence. The strongest strain in its Gut Health formula, HN019, has its own trial history, but it's a mixed and more limited one, and it doesn't come from a study of the finished WonderBiotics capsule. A 2011 dose-response trial in 100 adults with functional GI symptoms and an average of 1–3 bowel movements per week at baseline found that a high dose of HN019 alone (17.2 billion CFU/day) shortened total colonic transit time over 14 days, with a significant three-group comparison (P<0.001); the trial didn't report a direct high-dose-vs-placebo pairwise P-value⁵. WonderBiotics doesn't publish how much of its 60 billion CFU total is HN019 specifically, so it's not possible to say whether the capsule's HN019 dose comes close to the 17.2 billion CFU used in that trial. A larger 2018 trial in 228 adults tested HN019 at 1 and 10 billion CFU/day and found no significant difference between HN019 and placebo on its pre-specified primary or secondary endpoints, including colonic transit time and weekly bowel movements⁶. A post-hoc subgroup of people with fewer than three bowel movements per week did show more frequent stools with HN019 (P=0.01), and straining improved in the high-dose group specifically (P=0.02); those were exploratory, post-hoc findings inside a trial whose pre-specified primary and secondary endpoints were negative⁶. A 2024 systematic review and meta-analysis of 10 probiotic-for-constipation trials (1,243 patients) that included this HN019 trial confirmed it "did not find significant differences...in the primary or secondary outcomes"⁷; both HN019 trials were funded by the strain's manufacturer.

Seed ran its actual finished, multi-strain capsule through a large, recent trial. WonderBiotics' formula leans on published research for one of its individual strains (HN019), and that strain's own trial record is mixed rather than uniformly positive.

Why Neither Is Proven Specifically for Semaglutide or Tirzepatide Users

As of this writing, there is no published randomized trial testing Seed DS-01, WonderBiotics Probiotics for Gut Health, or any other probiotic or synbiotic specifically in people taking semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro). The only registered trial we found designed to test a probiotic alongside GLP-1 therapy, a French study planning to enroll 50 people starting GLP-1 treatment, was still listed as "not yet recruiting" in our August 2026 search of ClinicalTrials.gov; that record was last verified in October 2025, and its own estimated December 2025 start date has already passed without an update⁹.

GLP-1 medications slow gastric emptying and commonly cause nausea, diarrhea, vomiting, and constipation, with any GI side effect reported in roughly 73% of people on semaglutide 2.4 mg versus 47% on placebo in the drug's own label data⁸. That's a large, mechanistically distinct set of GI changes, driven by a receptor-level effect on gut motility, that a general-population bloating trial (Seed's) or a general-population transit-time trial (WonderBiotics' HN019 studies) simply wasn't designed to capture.

Because of that, neither product should be framed, by us or by Seed, as something that treats or resolves GLP-1 side effects. Both are better understood as daily digestive support layered into a GLP-1 routine rather than a treatment for the drug's mechanism of action. If nausea, vomiting, constipation, or bloating is severe, new, or getting worse, that's a conversation for the clinician who prescribed your medication, and you should never adjust or stop a prescribed GLP-1 dose on your own.

Which One Fits Your GLP-1 Routine

If what you want is the single largest, most recently published trial behind a full multi-strain formula, and you don't mind two capsules a day, a higher price, and CFUs shared across skin, heart, and micronutrient blends you may not need, Seed DS-01 is the more evidence-backed pick for bloating and regularity specifically, based on its own trial in a general adult population².

We built WonderBiotics Probiotics for Gut Health with a different reader in mind: someone managing smaller, slower meals on a GLP-1 medication who wants one capsule a day that pairs digestive enzymes with a higher total CFU count in a single gut-focused formula, at a lower monthly cost than Seed's subscription⁴. The five-enzyme blend pairs digestive enzymes with probiotics, addressing two different parts of digestion (breaking food down and supporting the bacteria that ferment what's left); that specific combination hasn't been clinically tested in GLP-1 users. HN019's own trial record is mixed rather than uniformly positive, and we haven't run a trial on the finished WonderBiotics capsule itself; a full-formula trial is a bigger undertaking than a single-strain one. WonderBiotics was built specifically as a GLP-1 companion product, at a price and dosing schedule designed to be easy to stick with alongside a weekly injection routine.

When to Call Your Doctor Instead of Reaching for a Probiotic

A probiotic, whichever brand you choose, is not the right tool for severe or alarming symptoms. Abdominal pain that's severe, persistent, or radiates to your back, especially with nausea, vomiting, fever, or chills, needs same-day medical attention. These are the flagged symptoms for pancreatitis and gallbladder problems, both of which occur somewhat more often on GLP-1 medications than on placebo^{8, 10}. Yellowing skin or eyes, dark urine, or an inability to pass gas or stool are also reasons to call your doctor rather than waiting to see if a supplement helps.

References

1. Seed. DS-01® Daily Synbiotic. Accessed August 2026.
2. Allegretti JR, Kassam Z, Kelly CR, et al. A Randomized, Placebo-Controlled Trial Evaluating Multi-Species Synbiotic Supplementation for Bloating, Gas, and Abdominal Discomfort. Nutrients. 2026;18(2):255. PMID 41599868
3. Bron PA, Catalayud M, Marzorati M, Pane M, Kartal E, Dhir R, Reid G. Delivery of Metabolically Neuroactive Probiotics to the Human Gut. Int J Mol Sci. 2021;22(17):9122. PMID 34502031
4. WonderBiotics. Probiotics for Gut Health. Accessed August 2026.
5. Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064. PMID 21663486
6. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. PMID 29227175
7. Garzon Mora N, Jaramillo AP. Effectiveness of Probiotics in Patients With Constipation: A Systematic Review and Meta-Analysis. Cureus. 2024;16(1):e52013. PMID 38344541
8. FDA. Wegovy (semaglutide) Prescribing Information. DailyMed, accessed August 2026.
9. ClinicalTrials.gov. Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment (PROBIO-GLP1). NCT07213323, Hospices Civils de Lyon.
10. NIDDK. Pancreatitis: Symptoms & Causes; Gallstones: Symptoms & Causes.